Skip to main content
SpringerLink
Log in

Cutaneous Lymphomas

  • Chapter
  • First Online:
Book cover A Practical Guide to Skin Cancer

  • 1274 Accesses

Abstract

Cutaneous B-cell and T-cell lymphomas are distinct subtypes of non-Hodgkin lymphoma (NHL). They are cancers of lymphocytes that primarily involve the skin, the most common single-organ location of extranodal NHL (Groves et al., J Natl Cancer Inst. 2000;92(15):1240–1251). Cutaneous lymphomas may remain limited to the skin for long periods of time but can spread to blood, lymph nodes, and viscera in cases of advanced disease. Cutaneous T-cell lymphomas (CTCL), involving malignant clonal T cells that present primarily in the skin, comprise more than 75% of all primary cutaneous lymphomas (Willemze et al., Blood. 2005;105(10):3768–3785). CTCL includes variants with indolent, aggressive, and variable clinical behavior, with mycosis fungoides (MF) and Sézary syndrome (SS) together comprising more than 50% of all CTCLs (Willemze et al., Blood. 2005;105(10):3768–3785). The second most common type of CTCL, CD30+ lymphoproliferative disorders, comprises 20% of all cutaneous lymphomas. Cutaneous B-cell lymphoma (CBCL) is less common and often presents as indolent disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92(15):1240–51.

    Article  PubMed  CAS  Google Scholar 

  2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.

    Article  PubMed  CAS  Google Scholar 

  3. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143(7):854–9.

    Article  PubMed  Google Scholar 

  4. National Center for Health Statistics. Health, United States. Health, United States, 2005: with chartbook on trends in the health of Americans. Hyattsville: National Center for Health Statistics (US); 2005.

    Google Scholar 

  5. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Zic JA, Zwerner ZJ, McGirt LY, Mosse CA, Greer JP. Cutaneous T cell lymphoma: mycosis fungoides and sézary syndrome. In: Greer JP, Arber DA, Glader B, List AF, Means RT, Paraskevas F, Rodgers GM, editors. Wintrobe’s clinical hematology. 13th ed. Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins; 2013.

    Google Scholar 

  7. Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149(11):1295–9.

    Article  PubMed  Google Scholar 

  8. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–34.

    Article  PubMed  CAS  Google Scholar 

  9. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–66.

    Article  PubMed  Google Scholar 

  10. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science (New York, NY). 1996;272(5258):60–6.

    Article  CAS  Google Scholar 

  11. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798–812.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Flier J, Boorsma DM, van Beek PJ, Nieboer C, Stoof TJ, Willemze R, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 2001;194(4):398–405.

    Article  PubMed  CAS  Google Scholar 

  13. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207.

    Article  PubMed  CAS  Google Scholar 

  14. Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P, et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood. 2007;110(12):3827–32.

    Article  PubMed  CAS  Google Scholar 

  15. Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4(117):117ra7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(10 Pt 1):3625–34.

    CAS  Google Scholar 

  17. Lu D, Duvic M, Medeiros LJ, Luthra R, Dorfman DM, Jones D. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol. 2001;115(3):413–21.

    Article  PubMed  CAS  Google Scholar 

  18. Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol. 2003;121(5):1045–52.

    Article  PubMed  CAS  Google Scholar 

  19. Kakinuma T, Sugaya M, Nakamura K, Kaneko F, Wakugawa M, Matsushima K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol. 2003;48(1):23–30.

    Article  PubMed  Google Scholar 

  20. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405–10.

    Article  PubMed  CAS  Google Scholar 

  21. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature. 1999;400(6746):776–80.

    Article  PubMed  CAS  Google Scholar 

  22. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood. 2002;99(8):2929–39.

    PubMed  CAS  Google Scholar 

  23. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet (London, England). 2008;371(9616):945–57.

    Article  CAS  Google Scholar 

  24. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15(5):787–93.

    Article  PubMed  CAS  Google Scholar 

  25. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci U S A. 1996;93(17):9148–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, Mustelin T, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A. 1997;94(13):6764–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol. 2009;129(5):1165–73.

    Article  PubMed  CAS  Google Scholar 

  28. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Mao X, Lillington D, Scarisbrick JJ, Mitchell T, Czepulkowski B, Russell-Jones R, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol. 2002;147(3):464–75.

    Article  PubMed  CAS  Google Scholar 

  30. van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(17):3886–96.

    Article  CAS  Google Scholar 

  31. Lin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, et al. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. J Invest Dermatol. 2012;132(1):188–97.

    Article  PubMed  CAS  Google Scholar 

  32. (NCCN) NCCN. Clinical practice guidelines in oncology: T cell lymphomas (Version 1.2017) 2017. Available from: https://www.nccn.org/professionals/physician_gls/recently_updated.asp.

  33. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of cancer (EORTC). Blood. 2007;110(6):1713–22.

    Article  PubMed  CAS  Google Scholar 

  34. Bernengo MG, Novelli M, Quaglino P, Lisa F, De Matteis A, Savoia P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating Sezary cells. Br J Dermatol. 2001;144(1):125–35.

    Article  PubMed  CAS  Google Scholar 

  35. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(18):2598–607.

    Article  Google Scholar 

  36. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479–84.

    Article  PubMed  CAS  Google Scholar 

  37. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115(6):885–92.

    Article  PubMed  CAS  Google Scholar 

  38. Borowitz MJ, Weidner A, Olsen EA, Picker LJ. Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease. Leukemia. 1993;7(6):859–63.

    PubMed  CAS  Google Scholar 

  39. Kuchnio M, Sausville EA, Jaffe ES, Greiner T, Foss FM, McClanahan J, et al. Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression. Am J Clin Pathol. 1994;102(6):856–60.

    Article  PubMed  CAS  Google Scholar 

  40. Abel EA, Lindae ML, Hoppe RT, Wood GS. Benign and malignant forms of erythroderma: cutaneous immunophenotypic characteristics. J Am Acad Dermatol. 1988;19(6):1089–95.

    Article  PubMed  CAS  Google Scholar 

  41. Harmon CB, Witzig TE, Katzmann JA, Pittelkow MR. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol. 1996;35(3 Pt 1):404–10.

    Article  PubMed  CAS  Google Scholar 

  42. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46(1):95–106.

    Article  PubMed  Google Scholar 

  43. Robson A. The pathology of cutaneous T-cell lymphoma. Oncology (Williston Park, NY). 2007;21(2 Suppl 1):9–12.

    Google Scholar 

  44. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol. 1988;132(2):265–77.

    PubMed  PubMed Central  CAS  Google Scholar 

  45. Cotta AC, Cintra ML, de Souza EM, Chagas CA, Magna LA, Fleury RN, et al. Diagnosis of mycosis fungoides: a comparative immunohistochemical study of T-cell markers using a novel anti-CD7 antibody. Appl Immunohistochem Mol Morphol AIMM. 2006;14(3):291–5.

    Article  PubMed  CAS  Google Scholar 

  46. Campbell SM, Peters SB, Zirwas MJ, Wong HK. Immunophenotypic diagnosis of primary cutaneous lymphomas: a review for the practicing dermatologist. J Clin Aesthetic Dermatol. 2010;3(10):21–5.

    Google Scholar 

  47. Gerami P, Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007;31(9):1430–8.

    Article  PubMed  Google Scholar 

  48. Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144(6):738–46.

    Article  PubMed  Google Scholar 

  49. Hale C. Woringer-Kolopp disease: Pathology Outlines; 2016, updated October 10, 2016. Available from: http://www.pathologyoutlines.com/topic/skintumornonmelanocyticworingerkolopp.html.

  50. Tsang WY, Chan JK, Loo KT, Wong KF, Lee AW. Granulomatous slack skin. Histopathology. 1994;25(1):49–55.

    Article  PubMed  CAS  Google Scholar 

  51. Werner B, Brown S, Ackerman AB. “Hypopigmented mycosis fungoides” is not always mycosis fungoides! Am J Dermatopathol. 2005;27(1):56–67.

    Article  PubMed  Google Scholar 

  52. Poszepczynska-Guigne E, Schiavon V, D’Incan M, Echchakir H, Musette P, Ortonne N, et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol. 2004;122(3):820–3.

    Article  PubMed  CAS  Google Scholar 

  53. Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int. 2008;58(2):89–97.

    Article  PubMed  Google Scholar 

  54. Wood GS, Tung RM, Haeffner AC, Crooks CF, Liao S, Orozco R, et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol. 1994;103(1):34–41.

    Article  PubMed  CAS  Google Scholar 

  55. Kim YH. Clinical issues in cutaneous T-cell lymphoma. American Academy of Dermatology annual meeting, Miami Beach; 2013.

    Google Scholar 

  56. Zhang B, Beck AH, Taube JM, Kohler S, Seo K, Zwerner J, et al. Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diag JMD. 2010;12(3):320–7.

    Article  Google Scholar 

  57. Thurber SE, Zhang B, Kim YH, Schrijver I, Zehnder J, Kohler S. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol. 2007;57(5):782–90.

    Article  PubMed  Google Scholar 

  58. Kirsch IR, Watanabe R, O’Malley JT, Williamson DW, Scott LL, Elco CP, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308):308ra158.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Lovendorf MB, Ahler CB, Svensson L, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011;118(22):5891–900.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4730–9.

    Article  Google Scholar 

  61. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis Fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(32):3766–73.

    Article  CAS  Google Scholar 

  62. Sun G, Berthelot C, Li Y, Glass DA 2nd, George D, Pandya A, et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol. 2009;60(2):231–5.

    Article  PubMed  Google Scholar 

  63. Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(18):5051–60.

    Article  CAS  Google Scholar 

  64. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol. 2009;48(3):243–52.

    Article  PubMed  Google Scholar 

  65. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J Am Acad Dermatol. 1999;40(6 Pt 1):914–24.

    Article  PubMed  CAS  Google Scholar 

  66. Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008;112(8):3082–7.

    Article  PubMed  CAS  Google Scholar 

  67. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(15):2908–25.

    Article  CAS  Google Scholar 

  68. Kural YB, Su O, Onsun N, Uras AR. Atopy, IgE and eosinophilic cationic protein concentration, specific IgE positivity, eosinophil count in cutaneous T cell lymphoma. Int J Dermatol. 2010;49(4):390–5.

    Article  PubMed  CAS  Google Scholar 

  69. Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary T cells. Arch Dermatol. 1993;129(4):486–9.

    Article  PubMed  CAS  Google Scholar 

  70. Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol. 2012;132(3 Pt 1):703–10.

    Article  PubMed  CAS  Google Scholar 

  71. Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155(2):483–92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33(12):1860–8.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol. 1996;132(1):42–7.

    Article  PubMed  CAS  Google Scholar 

  74. Hassel JC, Meier R, Joller-Jemelka H, Burg G, Dummer R. Serological immunomarkers in cutaneous T cell lymphoma. Dermatology (Basel, Switzerland). 2004;209(4):296–300.

    Article  CAS  Google Scholar 

  75. Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(3):575–83.

    Article  PubMed  CAS  Google Scholar 

  76. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457–70.

    Article  PubMed  CAS  Google Scholar 

  77. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol Off J Am Soc Clin Oncol. 1994;12(4):793–7.

    Article  CAS  Google Scholar 

  78. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol. 1995;32(3):448–53.

    Article  PubMed  CAS  Google Scholar 

  79. Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia. 2007;21(12):2512–8.

    Article  PubMed  CAS  Google Scholar 

  80. Li S, Ross DT, Kadin ME, Brown PO, Wasik MA. Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. Am J Pathol. 2001;158(4):1231–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood. 2007;110(8):3015–27.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Tracey L, Villuendas R, Dotor AM, Spiteri I, Ortiz P, Garcia JF, et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood. 2003;102(3):1042–50.

    Article  PubMed  CAS  Google Scholar 

  83. Martinez-Escala ME, Gonzalez BR, Guitart J. Mycosis Fungoides Variants. Surg Pathol Clin. 2014;7(2):169–89.

    Article  PubMed  Google Scholar 

  84. Talpur R, Bassett R, Duvic M. Prevalence and treatment of staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol. 2008;159(1):105–12.

    Article  PubMed  CAS  Google Scholar 

  85. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996;132(11):1309–13.

    Article  PubMed  CAS  Google Scholar 

  86. Gathers RC, Scherschun L, Malick F, Fivenson DP, Lim HW. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol. 2002;47(2):191–7.

    Article  PubMed  Google Scholar 

  87. Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk HH Jr, Prinz BM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005;141(3):305–11.

    Article  PubMed  Google Scholar 

  88. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165–73.

    PubMed  CAS  Google Scholar 

  89. Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52(2):275–80.

    Article  PubMed  Google Scholar 

  90. Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286–92.

    Article  PubMed  Google Scholar 

  91. Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81.

    Article  PubMed  CAS  Google Scholar 

  92. Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis Fungoides and Sézary syndrome: a European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended Analysis. J Clin Oncol. 2014;32(29):3347–8.

    Article  PubMed  Google Scholar 

  93. Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2009;15(8):982–90.

    Article  Google Scholar 

  94. Watanabe R, Teague JE, Fisher DC, Kupper TS, Clark RA. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol. 2014;150(7):776–9.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Latkowski JA, Heald P. Strategies for treating cutaneous T-cell lymphoma: part 1: remission. J Clin Aesthetic Dermatol. 2009;2(6):22–7.

    Google Scholar 

  96. Dalton JA, Yag-Howard C, Messina JL, Glass LF. Cutaneous T-cell lymphoma. Int J Dermatol. 1997;36(11):801–9.

    Article  PubMed  CAS  Google Scholar 

  97. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. JAMA. 1992;267(10):1354–8.

    Article  PubMed  CAS  Google Scholar 

  98. Drake LA, Cohen L, Gillies R, Flood JG, Riordan AT, Phillips SB, et al. Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. J Am Acad Dermatol. 1999;41(2 Pt 1):209–14.

    Article  PubMed  CAS  Google Scholar 

  99. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55(3):543–4.

    Article  PubMed  Google Scholar 

  100. Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med. 2009;361(14):1415–6.

    Article  PubMed  CAS  Google Scholar 

  101. Sugaya M, Morimura S, Suga H, Kawaguchi M, Miyagaki T, Ohmatsu H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol. 2015;42(6):613–5.

    Article  PubMed  CAS  Google Scholar 

  102. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother CII. 2009;58(8):1195–206.

    Article  PubMed  CAS  Google Scholar 

  103. Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(11):1157–63.

    Article  CAS  Google Scholar 

  106. Kantekure K, Yang Y, Raghunath P, Schaffer A, Woetmann A, Zhang Q, et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol. 2012;34(1):126–8.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on cd4+ t cells in cutaneous t-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146(12):1382–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Kim YH. A phase 2 study of pembrolizumab for the treatment of relapsed/refractory MF/SS. T-cell lymphoma forum 2016; January 28, 2016; San Francisco; 2016.

    Google Scholar 

  109. Khodadoust M RA, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, Shanbhag S, Sokol L, Shine R, Fling SP, Li S, Rabhar Z, Kim J, Yang Y, Yearley J, Chartash EK, Townson SM, Subrahmanyam PB, Maecker H, Alizadeh AA, Dai J, Horwitz SM, Sharon E, Kohrt H, Cheever MA, Kim YH. Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and Sezary syndrome: clinical efficacy in a CITN multicenter phase 2 study. 3rd World Congress of Cutaneous Lymphomas; October 28, 2016.

    Google Scholar 

  110. S T, editor. T cell symposium and USCLC meeting highlights United States Cutaneous Lymphoma Consortium (USCLC) cutaneous lymphoma workshop; 2016; Washington, DC.

    Google Scholar 

  111. Rozati S, Kim YH. Experimental treatment strategies in primary cutaneous T-cell lymphomas. Curr Opin Oncol. 2016;28(2):166–71.

    Article  PubMed  CAS  Google Scholar 

  112. Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014;74(21):6060–70.

    Article  PubMed  CAS  Google Scholar 

  113. Querfeld C, Pacheco T, Foss FM, Halwani AS, Porcu P, Seto AG, Ruckman J, Landry ML, Jackson AL, Pestano LA, Dickinson BA, Sanseverino M, Rodman DM, Gordon G, Marshall W. Preliminary results of a phase 1 trial evaluating MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL. Cancer. 2016;118(23):5830–9.

    Google Scholar 

  114. Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, et al. Resimmune, an anti-CD3epsilon recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015;100(6):794–800.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Kim YH. A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacetylase inhibitor (HDAC-i) SHP-141. American Society of Clinical Oncology (ASCO); Chicago; 2014.

    Google Scholar 

  116. Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010;63(6):984–90.

    Article  PubMed  CAS  Google Scholar 

  117. Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Duvic M, Kuzel T, Dang N, et al. A dose finding lead-in study of E777 (diphtheria toxin fragment-interleukin-2 fusion protein) in persistent or recurrent cutaneous T-cell lymphoma (CTCL). Blood. 2014;124(21):3097.

    Google Scholar 

  119. Schlaak M, Theurich S, Pickenhain J, Skoetz N, Kurschat P, von Bergwelt-Baildon M. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review. Crit Rev Oncol Hematol. 2013;85(1):21–31.

    Article  PubMed  CAS  Google Scholar 

  120. Foss FM, Sausville EA. Prognosis and staging of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1011–9.

    Article  PubMed  CAS  Google Scholar 

  121. Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(12):1581–7.

    Article  Google Scholar 

  122. Massone C, Fink-Puches R, Laimer M, Rutten A, Vale E, Cerroni L. Miliary and agminated-type primary cutaneous follicle center lymphoma: report of 18 cases. J Am Acad Dermatol. 2011;65(4):749–55.

    Article  PubMed  Google Scholar 

  123. Hamilton SN, Wai ES, Tan K, Alexander C, Gascoyne RD, Connors JM. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. Int J Radiat Oncol Biol Phys. 2013;87(4):719–25.

    Article  PubMed  Google Scholar 

  124. Cerroni L, Kerl H. Primary cutaneous follicle center cell lymphoma. Leuk Lymphoma. 2001;42(5):891–900.

    Article  PubMed  CAS  Google Scholar 

  125. Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139(4):515–35.

    Article  PubMed  CAS  Google Scholar 

  126. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90(1):354–71.

    PubMed  CAS  Google Scholar 

  127. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood. 1994;84(5):1361–92.

    PubMed  CAS  Google Scholar 

  128. Gulia A, Saggini A, Wiesner T, Fink-Puches R, Argenyi Z, Ferrara G, et al. Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment. J Am Acad Dermatol. 2011;65(5):991–1000.

    Article  PubMed  Google Scholar 

  129. Hoefnagel JJ, Vermeer MH, Jansen PM, Heule F, van Voorst Vader PC, Sanders CJ, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol. 2005;141(9):1139–45.

    Article  PubMed  CAS  Google Scholar 

  130. Xie X, Sundram U, Natkunam Y, Kohler S, Hoppe RT, Kim YH, et al. Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. Modern Pathol Off J United States Can Acad Pathol Inc. 2008;21(6):653–9.

    Article  CAS  Google Scholar 

  131. Li C, Inagaki H, Kuo TT, Hu S, Okabe M, Eimoto T. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. Am J Surg Pathol. 2003;27(8):1061–9.

    Article  PubMed  Google Scholar 

  132. Connors JM, Hsi ED, Foss FM. Lymphoma of the skin. Hematol Am Soc Hematol Educ Program. 2002;1:263–82.

    Google Scholar 

  133. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Grange F, Hedelin G, Joly P, Beylot-Barry M, D’Incan M, Delaunay M, et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sezary syndrome. The French study group on cutaneous lymphomas. Blood. 1999;93(11):3637–42.

    PubMed  CAS  Google Scholar 

  135. Koens L, Vermeer MH, Willemze R, Jansen PM. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. Am J Surg Pathol. 2010;34(7):1043–8.

    Article  PubMed  Google Scholar 

  136. Demirkesen C, Tuzuner N, Esen T, Lebe B, Ozkal S. The expression of IgM is helpful in the differentiation of primary cutaneous diffuse large B cell lymphoma and follicle center lymphoma. Leuk Res. 2011;35(9):1269–72.

    Article  PubMed  CAS  Google Scholar 

  137. Grange F, Petrella T, Beylot-Barry M, Joly P, D’Incan M, Delaunay M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103(10):3662–8.

    Article  PubMed  CAS  Google Scholar 

  138. Hallermann C, Niermann C, Fischer RJ, Schulze HJ. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas. J Am Acad Dermatol. 2007;56(4):588–97.

    Article  PubMed  Google Scholar 

  139. Koens L, Senff NJ, Vermeer MH, Willemze R, Jansen PM. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: a clinicopathologic and immunophenotypical study of 10 cases. Am J Surg Pathol. 2014;38(7):999–1006.

    Article  PubMed  Google Scholar 

  140. Geelen FA, Vermeer MH, Meijer CJ, Van der Putte SC, Kerkhof E, Kluin PM, et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(6):2080–5.

    Article  CAS  Google Scholar 

  141. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600–9.

    Article  PubMed  CAS  Google Scholar 

  142. Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144–50.

    Article  PubMed  Google Scholar 

  143. Gupta E, Accurso J, Sluzevich J, Menke DM, Tun HW. Excellent outcome of immunomodulation or Bruton’s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Rare Tumors. 2015;7(4):6067.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653–61.

    PubMed  CAS  Google Scholar 

  145. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  146. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoprolioerative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28(6):973–80.

    Article  PubMed  CAS  Google Scholar 

  147. Cerroni L. Lymphomatoid papulosis, pityriasis lichenoides et varioliformis acuta, and anaplastic large-cell (Ki-1+) lymphoma. J Am Acad Dermatol. 1997;37(2 Pt 1):287.

    Article  PubMed  CAS  Google Scholar 

  148. Brosens DA, Thulliez A. Histio-monocytic reticulosis and mycosis fungoides; four case reports. Arch Belg Dermatol Syphiligr. 1956;12(3):263–72.

    PubMed  CAS  Google Scholar 

  149. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign – histologically malignant. Arch Dermatol. 1968;97(1):23–30.

    Article  PubMed  CAS  Google Scholar 

  150. Willemze R, Meyer CJ, Van Vloten WA, Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol. 1982;107(2):131–44.

    Article  PubMed  CAS  Google Scholar 

  151. Cardoso J, Duhra P, Thway Y, Calonje E. Lymphomatoid papulosis type D: a newly described variant easily confused with cutaneous aggressive CD8-positive cytotoxic T-cell lymphoma. Am J Dermatopathol. 2012;34(7):762–5.

    Article  PubMed  Google Scholar 

  152. Kempf W, Kazakov DV, Baumgartner HP, Kutzner H. Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings. J Am Acad Dermatol. 2013;68(5):809–16.

    Article  PubMed  Google Scholar 

  153. Karai LJ, Kadin ME, Hsi ED, Sluzevich JC, Ketterling RP, Knudson RA, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37(8):1173–81.

    Article  PubMed  Google Scholar 

  154. Kaudewitz P, Stein H, Dallenbach F, Eckert F, Bieber K, Burg G, et al. Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical-characteristics. Am J Pathol. 1989;135(2):359–67.

    PubMed  PubMed Central  CAS  Google Scholar 

  155. Delsol G, Al Saati T, Gatter KC, Gerdes J, Schwarting R, Caveriviere P, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol. 1988;130(1):59–70.

    PubMed  PubMed Central  CAS  Google Scholar 

  156. Krenacs L, Wellmann A, Sorbara L, Himmelmann AW, Bagdi E, Jaffe ES, et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin’s disease: evidence for distinct cellular origin. Blood. 1997;89(3):980–9.

    PubMed  CAS  Google Scholar 

  157. Wilson MS, Weiss LM, Gatter KC, Mason DY, Dorfman RF, Warnke RA. Malignant histiocytosis. A reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies. Cancer. 1990;66(3):530–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Washington University in St. Louis, School of Medicine, St. Louis, MO, USA

    Trisha Bhat

  2. Department of Medicine, Division of Dermatology, Vanderbilt University, Nashville, TN, USA

    Jeffrey P. Zwerner

  3. Dermatology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA

    Amy Musiek

Authors
  1. Trisha Bhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey P. Zwerner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy Musiek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy Musiek .

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Allison Hanlon

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bhat, T., Zwerner, J.P., Musiek, A. (2018). Cutaneous Lymphomas. In: Hanlon, A. (eds) A Practical Guide to Skin Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-74903-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74903-7_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74901-3

  • Online ISBN: 978-3-319-74903-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation